Corcept Therapeutics Incorporated (CORT)

Market Cap	3.81B -46.2%
Revenue (ttm)	761.41M +12.8%
Net Income	98.17M -29.4%
EPS	0.82 -33.3%
Shares Out	106.37M
PE Ratio	43.63
Forward PE	90.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,576,920
Open	36.47
Previous Close	36.22
Day's Range	34.50 - 36.47
52-Week Range	28.66 - 117.33
Beta	0.26
Analysts	Buy
Price Target	105.20 (+194.02%)
Earnings Date	Feb 24, 2026

About CORT

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortis...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 730
• Stock Exchange: NASDAQ
• Ticker Symbol: CORT
• Website: https://www.corcept.com

Financial Performance

In 2025, Corcept Therapeutics's revenue was $761.41 million, an increase of 12.79% compared to the previous year's $675.04 million. Earnings were $98.17 million, a decrease of -29.74%.

Analyst Summary

According to 6 analysts, the average rating for CORT stock is "Buy." The 12-month stock price target is $105.2, which is an increase of 194.02% from the latest price.

Price Target

$105.2

(194.02% upside)

Analyst Consensus: Buy